ArticleAdvanced healthcare materials2025
Bioassembly of Region-Specific Fibrocartilage Microtissues to Engineer Zonally Defined Meniscal Grafts.
Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bioassembly of Region-Specific Fibrocartilage Microtissues to Engineer Zonally Defined Meniscal Grafts.Advanced healthcare materials · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Meniscal injuries are common orthopaedic problems which can impair knee function and lead to the development of osteoarthritis. While recent advances in tissue engineering have enabled the fabrication of meniscus-like grafts, these do not fully replicate the zonal structure and composition of the native meniscus. Here, fibrocartilage microtissues are used as building blocks to biofabricate zonally defined meniscal grafts. Meniscus progenitor cells (MPCs) isolated from the inner (iMPC) and outer (oMPC) regions of caprine menisci are used to engineer region-specific meniscal microtissues. Both iMPC and oMPC-derived microtissues are rich in glycosaminoglycans (GAGs) and collagen, with iMPC-derived microtissues staining more intensely for type II collagen. These microtissues are assembled into two different physically confining moulds, where they rapidly fuse and generate a fibrocartilaginous graft. The impact of the catabolic enzyme chondroitinase-ABC (cABC) on the composition and structural organization of the meniscal grafts is then explored, which is found to reduce sGAG levels but to increase collagen fiber thickness. Finally, iMPC and oMPC microtissues are spatially assembled to biofabricate a scaled-up and zonally defined meniscal construct. These findings support the use of MPC-derived microtissues as biological building blocks for the engineering of meniscal grafts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.